The symposium will explore the value of 2L CAR-T-cell therapy, and how bispecific antibodies have shaped patient outcomes in RRMM. The first session will look at the latest data for 2L CAR-T, showcasing positive long-term results from clinical trials and real-world experiences. It will also explore how to identify appropriate patients for early CAR-T referral, considering how timely treatment decisions may enhance curative potential and optimise patient management in a real-world setting. The second session will cover how bispecific antibodies have redefined the RR treatment landscape, with growing experience of AE management and outpatient dosing supporting patient quality of life. This session will also consider how the role of bispecific antibodies may evolve as emerging combinations continue to demonstrate promising outcomes.
| AGENDA | |
|---|---|
| 12:05-12:10 | Welcome, introduction and opening discussion Prof. María-Victoria Mateos (Chair) to present and moderate discussion; all faculty to participate |
| 12:10-12:40 | Connecting the threads: early integration of CAR-T therapy Prof. Salomon Manier to present; Prof. María-Victoria Mateos (Chair) to moderate discussion |
| 12:40-13:15 | Transforming care: a new era for bispecific antibodies in RRMM Prof. Paula Rodríguez-Otero to present; Prof. María-Victoria Mateos (Chair) to moderate discussion |
| 13:15-13:20 | Close Prof. María-Victoria Mateos (Chair) |
EM-201660
Date of Prep: April 2026
